CompanyXBITNasdaqAustin, TX

XBiotech, Inc.

XBiotech develops True Human monoclonal antibodies for treating various diseases.

SEC EDGAR ClinicalTrials.gov

10-QAug 13Latest SEC filing, period to Jun 30

Aug 14Latest story

August 2026

XBiotech posts Phase 1 results for Natrunix dose-escalation study in healthy volunteers

Aug 14Trial updatenatrunix XBiotech, Inc.

XBiotech posts results for XB2001 pancreatic cancer trial, over five years after registration

Aug 4Trial updateXB2001 XBiotech, Inc.